Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00371332 · ClinicalTrials.gov registry record · Phase 3

Effect of Adjunctive Treatment With Arestin on the Subgingival Microflora in Patients With Moderate to Advanced Periodontitis

A Phase 3 study of Periodontitis, sponsored by OraPharma.

Completed
Registry status
Phase 3
Development phase
128
Enrollment target
5
Study locations

NCT00371332 is a Phase 3 study of Periodontitis that has completed, run by OraPharma. The registered enrollment target is 128 participants, above the 103-participant average among 11 other Periodontitis trials with a reported enrollment target (24% higher). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00371332, a Phase 3 study of Periodontitis, has completed, sponsored by OraPharma.

COMPLETED
Registry status
Phase 3
Development phase
128 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this study is to measure the antimicrobial effects of Arestin in subjects with moderate to advanced periodontal disease

Conditions Studied

Interventions

  • DRUG Minocycline HCL Microspheres

Study Locations (5)

California

  • - Los Angeles

Maryland

  • - Baltimore

Massachusetts

  • - Boston

New York

  • - Buffalo

Tennessee

  • - Memphis

Trial Details

FieldValue
Enrollment Target 128 participants
Start Date 2004-01
Phase Phase 3

Sponsor

OraPharma

5 total trials

What the Registry Record Tells You About NCT00371332

The ClinicalTrials.gov registry entry for NCT00371332 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 103-participant average among 11 other Periodontitis trials with a reported enrollment target (24% higher). The listed sponsor is OraPharma, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Periodontitis appearing as the primary indexed condition, and to 1 intervention - of which Minocycline HCL Microspheres is the first listed.

NCT00371332 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Maryland, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00371332 about?

NCT00371332 is a clinical study titled "Effect of Adjunctive Treatment With Arestin on the Subgingival Microflora in Patients With Moderate to Advanced Periodontitis". The purpose of this study is to measure the antimicrobial effects of Arestin in subjects with moderate to advanced periodontal disease

What is the current status of trial NCT00371332?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 128 participants. The study started on 2004-01.

What conditions does trial NCT00371332 study?

This clinical trial studies the following conditions: Periodontitis.

What interventions are being tested in trial NCT00371332?

The interventions under investigation include: Minocycline HCL Microspheres (DRUG).

Who is sponsoring clinical trial NCT00371332?

This trial is sponsored by OraPharma, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00371332 being conducted?

This trial has 5 study locations across California, Maryland, Massachusetts, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Periodontitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.